NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Yokogawa Electric Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Yokogawa and InSphero Enter into Partnership Agreement - Supporting drug development research through the use of HCA and three-dimensional culture models - InSphero.com / Yokogawa.com
Yokogawa and InSphero Enter into Partnership Agreement

 

NewswireToday - /newswire/ - Tokyo, Japan, 2020/12/03 - Supporting drug development research through the use of HCA and three-dimensional culture models - InSphero.com / Yokogawa.com. TOKYO: 6841

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Manufacturing / Robotics Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Yokogawa Electric Corporation announces that it has entered into a partnership agreement with InSphero AG, a pioneer in the development of 3D in vitro*1 technologies for drug discovery and safety. The two companies aim to establish and advance methods for the use of high-content analysis*2 (HCA) in drug discovery and safety assessment. They will jointly promote and support the use of high-value-added HCA solutions in drug discovery research that involves the use of 3D in vitro models*1.

Through its 3D InSight™ discovery and safety platforms, InSphero provides robust, physiologically optimized 3D in vitro solutions to the pharmaceutical and biotechnology industries. The company’s discovery and safety platforms have been adopted by major pharmaceutical companies around the world to inform decisions earlier in the drug discovery pipeline and better predict the patient response to new drugs and therapeutics. The scalable Akura™ technology underlying these platforms includes 96 and 384-well plate formats and an organ-on-a-chip system for integrating 3D spheroid models in multi-tissue and organ networks on a multichannel bio-functional chip. Precisely engineered for cell imaging and automated environments, InSphero platforms are suitable for a wide range of applications, from HCA to the investigation of complex interactions between spheroid tissue models.

Yokogawa’s CellVoyager high-throughput screening system series is equipped with the company’s CSU confocal scanner unit, which scans cells at high speed, enabling high resolution 3D imaging for the screening of candidate compounds. Furthermore, the deep learning function of the CellPathfinder high-content analysis software, enables complex image analysis techniques such as phenotypic analysis*3. Together, InSphero and Yokogawa will advance the use of HCA technologies and methodologies and thereby address the growing demand for these solutions in applications such as drug discovery. By using this technology to extract useful pharmacological information and elucidate the pathophysiology of diseases in complex multicellular 3D spheroid models, the two companies will contribute to the development of new drugs and advance human health.

As part of this partnership agreement, InSphero has begun using Yokogawa’s CQ1 confocal quantitative image cytometer in its ongoing drug discovery and safety programs. In the life science journal SLAS Discovery, the two companies have jointly published an article*4 about an optimal HCA method using 3D multicellular spheroid models for drug discovery. InSphero and Yokogawa will be able to make use of deep learning and other HCA capabilities to further study and develop new high-content imaging and analysis solutions for 3D in vitro models.

“Over the past few years, 3D in vitro models have clearly become the gold standard for drug discovery applications,” says InSphero CEO and Co-Founder Jan Lichtenberg, PhD. “Our portfolio of 3D InSight™ discovery and safety platforms provide several key advantages over 2D and animal models for research teams seeking more human cell-based models. We found the perfect HCA partner in Yokogawa to help us optimize our use of 3D imaging instrumentation and software and leverage their exceptional suite of tools for high quality 3D imaging for live cell analysis.”

Hiroshi Nakao, a Yokogawa vice president and head of the company’s Life Innovation Business Headquarters, says,“As one of our three long-term sustainability targets for the year 2050, we are working to ensure the well-being of all people. Through this partnership, we will be able to provide seamless services ranging from the construction of high-quality 3D in vitro models to complex analyses, thereby contributing to the improvement of screening technologies and the speed of drug discovery.”

About Yokogawa’s HCA solution

For a wide range of research applications, from basic research to drug discovery screening, Yokogawa’s life innovation business provides high-content analysis (HCA) systems, also known as high-content screening (HCS) systems. Paired with our advanced analysis software, these HCA systems provide high quality 3D imaging for enhanced live cell analysis, enabling researchers to identify substances such as small molecules, peptides, and RNAi that can alter the phenotype of a cell. High-resolution microscopic images captured with Yokogawa HCA instruments can be used to detect cellular phenotypic changes at a molecular level, making this a powerful tool for studying the effects of physiologically active substances such as siRNA, peptides, and antibodies on cultured cells, tissue samples, and whole organisms.

About InSphero

InSphero (insphero.com) is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.

*1 Three-dimensional culture model for in vitro studies (3D in vitro model)
Produced using cultured cells, 3D in vitro models are used in drug discovery to investigate the safety and efficacy of candidate compounds. They can be used to model tumours, liver fibrosis, and the like.

*2 High-content analysis (HCA)
HCA refers to a series of techniques that automatically and rapidly capture and analyze large amounts of images using microscope-based imaging systems.

*3 Phenotypic analysis
An analytical method for quantifying phenotypic changes using multiple parameters. It can be used to analyze the protein localization and morphological changes in cells and thereby determine whether a drug compound has the desired effects.

*4 Wardwell-Swanson, J., Suzuki, M., et al. A Framework for Optimizing High-Content Imaging of 3D Models for Drug Discovery, SLAS Discovery, June 2, 2020,
doi.org/10.1177/2472555220929291

About Yokogawa

Founded in 1915, Yokogawa (yokogawa.com) engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 114 companies spanning 62 countries, generating US$3.7 billion in sales in FY2019.

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of their respective holders.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Manufacturing / Robotics Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Yokogawa Electric Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Manufacturing / Robotics articles,
CATCH Visitors via Your Competitors Announcements!


Yokogawa and InSphero Enter into Partnership Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - Yokogawa.com 
+81 422-52-5535 press[.]yokogawa.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Yokogawa Electric Corporation securities in any jurisdiction including any other companies listed or named in this release.

Manufacturing / Robotics via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Yokogawa Electric Corporation / Company Profile


Read Manufacturing / Robotics Most Recent Related Newswires:

Panasonic Lauded by Frost & Sullivan for Logiscend, its Turnkey Solution Offering Material Visualization and Localization Capabilities
Yokogawa Bio Frontier Commences Sales of S-CNF - A High-Performance Nanocellulose Material
ABB Commissions Digital Platform Integration for Sunflag Steel to Enable Better Metals Plant Decision Making
BASF Receives GMP+ and ISO 22000 Certifications for its Glycerin Production At the Dusseldorf Site
ABB Launches First European Pulp and Paper Tour At ZELLCHEMING, Germany
Infineon is Co-founder of the Quantum Technology and Application Consortium
ABB Launches New Condition Monitoring Digital Service, Tailor-made for Predictive Maintenance of Conveyor Belts
Perceptron® Lauded by Frost & Sullivan for Enhancing the Manufacturing Inspection Process with its Automated Solution with AccuSite®
KLEINIG Engineering Develops Assembly Cell with Two MOTOMAN Robots
ABB Awarded Collaborative MES Agreement, Supporting Sappi’s Digital Transformation Across its Entire Production Fleet
BASF Concludes Sale of Site in Kankakee, Illinois, to One Rock Capital Partners
A New Facility is Being Established in The United States in Order to Collaborate and Create New Solutions with Customers
Yokogawa Releases Platform for Advanced Control and Estimation R5.03
Yokogawa Obtains ISASecure CSA Level 1 Certification for ProSafe-RS Safety Instrumented System
ANDRITZ Signs Industrial Maintenance Contract with Smurfit Kappa Nervion in Spain

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)